ACA repeal plans advance to House committees

Several key House committees have scheduled hearings regarding the Affordable Care Act (ACA), a sign Republicans don’t plan on slowing down the repeal process now that President Donald Trump has taken office.

According to the Washington Post, the process already began with January 24 meetings of the House Budget Committee entitled, “The Failures of Obamacare: Harmful Effects and Broken Promises,” and an examination of the law’s individual mandate by the House Ways and Means Committee.

Republicans could unify around a repeal plan after a scheduled weekend retreat in Philadelphia, which Trump is set to attend. Some hint of what’s decided during the retreat could come in hearings of the House Energy and Commerce Committee focused on lowering insurance premiums and making changes to Medicaid.

“Next week, the committee will begin taking action on legislation to help rebuild our health-care system with thoughtful, step-by-step reforms in order to bring badly needed relief to patients and families across the country,” said committee spokesperson Zach Hunter.

For more on what committee hearings are worth paying attention to, read the full article below:  

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.